30 April 2020

Safety Updates & Withdrawals for Pharmaceutical & Herbal Products

Reference: CIR-2019-00000183

To all health facilities / all health care practitioners in Dubai's private health sector:

Referring to the above subject, DHA notes all health facilities regarding the Circular issued by the MOHAP for information and adhere to what is stated

• Safety update of pharmaceutical product Lemtrade (Alemtuzumab) 12mg solution for infusion 
• Recall one batch of pharmaceutical product Sodium Chloride 0.9% w/v, 250ml
• Recall one batch of pharmaceutical product Phenobarb 5mg/ml Elixir 100ml
• Recall three batchs of pharmaceutical product Vitamin D3 50000 IU Capsule
• Recall all batch’s of pharmaceutical product Irsotan(Irbesartan) 150 & 300mg tablet
• Suspend registration & recall of herbal product Musli Power X-Tra Capsule

 

Thanks in advance for your good co-operation

Drug Control Section

Health Regulation Sector

DHA

Supporting Documents:

Safety update of pharmaceutical product Lemtrade (Alemtuzumab) 12mg solution for.pdf:

View Document

Recall one batch of pharmaceutical product Sodium Chloride 0.9%.pdf:

View Document

Recall one batch of pharmaceutical product Phenobarb 5mg-ml Elixir 100ml.pdf:

View Document

Recall three batchs of pharmaceutical product Vitamin D3 50000 IU Capsule.pdf:

View Document

Recall all batches of pharmaceutical product Irsotan(Irbesartan) 150 and 300mg tablet.pdf:

View Document

Suspend registration _ recall of herbal product Musli Power X-Tra Capsule.pdf:

View Document